Immatics Biotechnologies

About Immatics Biotechnologies

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules TCER®. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology. Privately-held Immatics was established in 2000 as a spin out from H.G. Rammensee's laboratory at the University of Tübingen, Germany. The Company was founded to develop and commercialize ground-breaking discoveries on the immunopeptidome as targets for all types of T-cell based immunotherapies. In 2015, Immatics and MD Anderson Cancer Center (MDACC) launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies. Immatics has more than 180 team members across its three sites. Our headquarter, discovery, research and Bispecific TCR development are in Tuebingen, while corporate, commercial and regulatory functions are in Munich. Adoptive cell therapy development and clinical manufacturing are carried out in Houston, Texas.. Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.

Synonyms

Technologies (from Job Ads)

Hiring Locations

Headquarters

Loading map...

Company Info

Legal Form: GmbH

Company Type: Private

Company Size: 51 - 250

Revenue: 5 - 25 billion (USD)

Job Ad Metrics

Job Ads found: 269

Job Ads per Month: 8.2

Hiring Locations: 4

Data Info